[go: up one dir, main page]

MX2022005258A - Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias. - Google Patents

Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.

Info

Publication number
MX2022005258A
MX2022005258A MX2022005258A MX2022005258A MX2022005258A MX 2022005258 A MX2022005258 A MX 2022005258A MX 2022005258 A MX2022005258 A MX 2022005258A MX 2022005258 A MX2022005258 A MX 2022005258A MX 2022005258 A MX2022005258 A MX 2022005258A
Authority
MX
Mexico
Prior art keywords
dhodh
inhibitors
cancer
treatment
autoimmune
Prior art date
Application number
MX2022005258A
Other languages
English (en)
Inventor
Zhuming Zhang
Scott Kuduk
Aihua Wang
Justin Cisar
Chao-Yuan Wang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022005258A publication Critical patent/MX2022005258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe compuestos de la Fórmula (I): (I) en donde X es CH; R2 es (AA) R es (BB) Los presentes compuestos de la Fórmula (I) son inhibidores de dihidroorotato deshidrogenasa (DHODH) y son útiles para el tratamiento de trastornos inflamatorios, trastornos autoinmunes y cáncer, tales como, p. ej., linfomas, leucemias, carcinomas y sarcomas. La presente descripción describe la síntesis y caracterización de compuestos ilustrativos así como datos farmacológicos de estos (p. ej., páginas 61 a 101; Ejemplos 1 a 24; Tablas 1 y 2). Un compuesto ilustrativo es, p. ej., 7-(4-etil-3-(hidroximetil)-5-oxo -4,5-dihidro-1H-1,2,4-triazol-1-il)-6-fluoro-3-(3-fluorofenil)-1- isopropilquinolin-4(1H)-ona (Ejemplo 1): (CC).
MX2022005258A 2019-11-01 2020-10-30 Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias. MX2022005258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962929160P 2019-11-01 2019-11-01
PCT/IB2020/060217 WO2021084498A1 (en) 2019-11-01 2020-10-30 Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2022005258A true MX2022005258A (es) 2022-06-09

Family

ID=73198373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005258A MX2022005258A (es) 2019-11-01 2020-10-30 Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.

Country Status (10)

Country Link
US (1) US20240166622A1 (es)
EP (1) EP4051671A1 (es)
JP (1) JP2023500305A (es)
KR (1) KR20220097439A (es)
CN (1) CN114630826A (es)
AU (1) AU2020373411A1 (es)
BR (1) BR112022008221A2 (es)
CA (1) CA3159211A1 (es)
MX (1) MX2022005258A (es)
WO (1) WO2021084498A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230037448A1 (en) * 2019-11-01 2023-02-09 Janssen Biotech, Inc. Fluorinated quinoline and quinoxaline derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases
CA3184985A1 (en) * 2020-07-14 2022-01-20 Nanjing Zenshine Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
WO2022200615A1 (en) 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894084A (en) * 1987-12-29 1990-01-16 Fmc Corporation Substituted quinolinonyl and dihydroquinolinonyl triazolinone herbicides
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer

Also Published As

Publication number Publication date
JP2023500305A (ja) 2023-01-05
EP4051671A1 (en) 2022-09-07
US20240166622A1 (en) 2024-05-23
WO2021084498A1 (en) 2021-05-06
BR112022008221A2 (pt) 2022-07-12
CA3159211A1 (en) 2021-05-06
KR20220097439A (ko) 2022-07-07
AU2020373411A1 (en) 2022-06-16
CN114630826A (zh) 2022-06-14

Similar Documents

Publication Publication Date Title
MX2022005258A (es) Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.
US10662204B2 (en) Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
US10709709B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY148986A (en) Heterocyclic janus kinase 3 inhibitors
ATE503483T1 (de) Hemmer der akt aktivität
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
RS50931B (sr) Derivati hinolina i izohinolina, postupak za njihovo dobijanje i njihova primena kao anti-inflamatornih sredstava
TWI884745B (zh) 甲狀腺素受體β促效劑化合物
WO2022115439A1 (en) Kras g12c inhibitors and uses thereof
WO2019132560A1 (ko) 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
CN107108579A (zh) 作为adamts抑制剂用于治疗骨关节炎的5‑[(哌嗪‑1‑基)‑3‑氧代‑丙基]‑咪唑烷‑2,4‑二酮衍生物
SA06270072B1 (ar) مشتقات جديدة من 7- امينو -[ 1، 3] ثيازولو [ 4، 5-d] بيريميدين بها استبدال في الموضع 5
KR950018008A (ko) 3-퀴놀론카르복실산 유도체의 단일-반응기 제조 방법
JP2022519383A (ja) ジヒドロオロト酸デヒドロゲナーゼ阻害剤
MA41494A (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MX2022005270A (es) Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.
MA64568B1 (fr) Composés hétérocycliques capables d'activer sting
MX2023007550A (es) Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k).
FI4259632T3 (fi) N-(imidatso[1,2-b]pyridatsin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidi- ja n-(pyratsolo[1,5-a]pyrimidin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidijohdannaisia irak4-estäjinä astman hoitoon
DK173330B1 (da) Pyrido(3,2,1-ij)-1,3,4-benzoxadiazin-derivater, en fremgangsmåde til fremstilling deraf, disse forbindelser til anvendelse
EP0028936A3 (en) 4-carbamoylimidazol-5-ol derivatives, their production and pharmaceutical compositions containing them
Wen et al. Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues
WO2016201219A1 (en) Small molecule inhibitors of dihydrofolate reductase
EP3089974A1 (en) Novel imidazolidine-2,4-dione derivatives
ES2014303B3 (es) Compuestos de bis-azolilo.